Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,512.38 -3.89 -0.03%
TOPIX 1,171.40 -1.97 -0.17%
HANG SENG 22,760.24 64.23 0.28%

WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan



 WaferGen Bio-systems and QIAGEN KK Sign Agreement for Co-Marketing in Japan

The Two Companies Will Jointly Promote WaferGen's SmartChip qPCR System
Together with QIAGEN's PCRarrays

PR Newswire

FREMONT, Calif., Feb. 19, 2013

FREMONT, Calif., Feb. 19, 2013 /PRNewswire/ -- WaferGen Bio-systems, Inc.
(OTCBB: WGBS) announced today a co-marketing agreement with QIAGEN KK – a
subsidiary of QIAGEN N.V.– for the joint promotion of certain products in
Japan in the areas of genomics platforms such as Next-Gen sequencing (NGS) and
qPCR.  With the joint offering, customers will be able to seamlessly plan and
execute complex research projects involving molecular biomarker discovery with
NGS, where WaferGen's SmartChip will offer a powerful platform for
high-throughput qPCR-based target validation.  The purpose of the commercial
relationship is to help life science researchers accelerate the process of
developing markers that are potential candidates for molecular diagnostics by
adding WaferGen's SmartChip solution to facilitate biomarker validation. 
Further customer-facing synergies will be achieved by offering QIAGEN's
PCRarrays on the SmartChip and subsequently compatible NGS panels from QIAGEN.

Stephane Perrey, President of QIAGEN KK stated: "We are looking forward to
expanding our portfolio of life science offerings in Japan through the
co-marketing of WaferGen's high-throughput qPCR solution.  There is a
substantial customer need to ramp up discovery efforts through targeted
screening and confirmation, and our integrated approach will provide one-stop
shopping for a variety of academic and industrial clients.  We will be able to
guide customers through the series of steps necessary for an effective
biomarker discovery and validation program, by providing both the
instrumentation and assays necessary for the accomplishment of their
scientific goals.  We have successfully evaluated WaferGen's SmartChip System,
and we believe that it can play an important role in our comprehensive product
offering."

"We are extremely pleased to be partnering in a joint commercial effort with
QIAGEN to bring our products to the research and industrial communities in
Japan," added Ivan Trifunovich, President and CEO of WaferGen.  "Our product
lines are highly complementary, together providing a total solution to our
customers' needs.  Since our July, 2012 launch of our MyDesign open format
instrument, we have received enthusiastically positive reviews from our early
test sites and commercial customers in the US and Europe.  In conjunction with
our highly-regarded partner, we look forward to building on these results in
Japan.  We are confident that our three-part value proposition – platform
flexibility, cost-effectiveness, and no need for pre-amplification – will be
strong drivers of customers' interest," Trifunovich added. 

Under the terms of the agreement, QIAGEN and WaferGen will promote and market
each other's products in Japan, specifically WaferGen's SmartChip platform and
QIAGEN 's NGS platform which is currently in an advanced stage of development.
This breakthrough next-generation benchtop sequencer is one element of
QIAGEN's initiative to create integrated NGS workflows that combine innovative
instrumentation and consumables into a sample-to-result offering planned for
launch later this year. The two teams will be working closely together in
terms of developing the overall strategy and tactical plan that will maximize
the commercial opportunity for both companies. 

About WaferGen and the SmartChip Real-Time PCR System

WaferGen Bio-systems, Inc. is an innovative life science company that offers
the SmartChip Real-Time PCR System—a next-generation genetic analysis platform
for profiling and validating thousands of molecular biomarkers in parallel. It
provides a range of high-throughput capabilities including microRNA and mRNA
gene expression profiling as well as single nucleotide polymorphism (SNP)
genotyping.

For additional information, please see http://www.wafergen.com

About QIAGEN

QIAGEN N.V., a Netherlands holding company, is the leading global provider of
Sample & Assay Technologies that are used to transform biological materials
into valuable molecular information. Sample technologies are used to isolate
and process DNA, RNA and proteins from biological samples such as blood or
tissue. Assay technologies are then used to make these isolated biomolecules
visible and ready for interpretation. QIAGEN markets more than 500 products
around the world, selling both consumable kits and automation systems to
customers through four customer classes: Molecular Diagnostics (human
healthcare), Applied Testing (forensics, veterinary testing and food safety),
Pharma (pharmaceutical and biotechnology companies) and Academia (life
sciences research). As of December 31, 2012, QIAGEN employed approximately
4,000 people in over 35 locations worldwide. QIAGEN KK is a wholly owned
subsidiary of QIAGEN NV of about 100 employees who market QIAGEN's entire
product portfolio across all Japanese customer classes. Further information
can be found at http://www.qiagen.com  

Forward Looking Statements

This press release contains certain "forward-looking statements."  Such
statements include statements relating to the expected benefits to the Company
of the relationship with QIAGEN KK combined with the features of its open
format qPCR platform and other statements relating to future events that are
not historical facts, including statements which may be preceded by the words
"will," "believes" or similar words. Forward-looking statements are not
guarantees of future performance, are based on certain assumptions and are
subject to various known and unknown risks and uncertainties, many of which
are beyond the control of the Company. Actual results may differ materially
from the expectations contained in the forward-looking statements. More
detailed information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the Company's
filings with the Securities and Exchange Commission, including the company's
Annual Report on Form 10-K for the year ended December 31, 2011. Security
holders are urged to read these documents free of charge on the SEC's web site
at www.sec.gov. The Company does not undertake to publicly update or revise
its forward-looking statements as a result of new information, future events
or otherwise.

WaferGen Contact:

John Harland
john.harland@wafergen.com
510-780-2395

SOURCE WaferGen Biosystems, Inc.

Website: http://www.wafergen.com
Website: http://www.qiagen.com
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement